310 related articles for article (PubMed ID: 20580798)
1. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Galmarini CM; Warren G; Senanayake MT; Vinogradov SV
Int J Pharm; 2010 Aug; 395(1-2):281-9. PubMed ID: 20580798
[TBL] [Abstract][Full Text] [Related]
2. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
Galmarini CM; Warren G; Kohli E; Zeman A; Mitin A; Vinogradov SV
Mol Cancer Ther; 2008 Oct; 7(10):3373-80. PubMed ID: 18852140
[TBL] [Abstract][Full Text] [Related]
3. Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Senanayake TH; Warren G; Wei X; Vinogradov SV
J Control Release; 2013 Apr; 167(2):200-9. PubMed ID: 23385032
[TBL] [Abstract][Full Text] [Related]
4. Novel anticancer polymeric conjugates of activated nucleoside analogues.
Senanayake TH; Warren G; Vinogradov SV
Bioconjug Chem; 2011 Oct; 22(10):1983-93. PubMed ID: 21863885
[TBL] [Abstract][Full Text] [Related]
5. Comparison of nanogel drug carriers and their formulations with nucleoside 5'-triphosphates.
Vinogradov SV; Kohli E; Zeman AD
Pharm Res; 2006 May; 23(5):920-30. PubMed ID: 16715382
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
7. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
9. Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Bergman AM; Pinedo HM; Jongsma AP; Brouwer M; Ruiz van Haperen VW; Veerman G; Leyva A; Eriksson S; Peters GJ
Biochem Pharmacol; 1999 Feb; 57(4):397-406. PubMed ID: 9933028
[TBL] [Abstract][Full Text] [Related]
10. A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types.
Reddy LH; Dubernet C; Mouelhi SL; Marque PE; Desmaele D; Couvreur P
J Control Release; 2007 Dec; 124(1-2):20-7. PubMed ID: 17878060
[TBL] [Abstract][Full Text] [Related]
11. Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Bergman AM; Munch-Petersen B; Jensen PB; Sehested M; Veerman G; Voorn DA; Smid K; Pinedo HM; Peters GJ
Biochem Pharmacol; 2001 Jun; 61(11):1401-8. PubMed ID: 11331076
[TBL] [Abstract][Full Text] [Related]
12. Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Hung SW; Marrache S; Cummins S; Bhutia YD; Mody H; Hooks SB; Dhar S; Govindarajan R
Cancer Lett; 2015 Apr; 359(2):233-40. PubMed ID: 25600708
[TBL] [Abstract][Full Text] [Related]
13. In vitro assessment of nucleoside analogs in multiple myeloma.
Krett NL; Ayres M; Nabhan C; Ma C; Nowak B; Nawrocki S; Rosen ST; Gandhi V
Cancer Chemother Pharmacol; 2004 Aug; 54(2):113-21. PubMed ID: 15133625
[TBL] [Abstract][Full Text] [Related]
14. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
15. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
16. [Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Tsukagoshi S
Gan To Kagaku Ryoho; 1999 Feb; 26(3):393-400. PubMed ID: 10065109
[TBL] [Abstract][Full Text] [Related]
17. Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.
Wonganan P; Lansakara-P DS; Zhu S; Holzer M; Sandoval MA; Warthaka M; Cui Z
J Control Release; 2013 Jul; 169(1-2):17-27. PubMed ID: 23570983
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Maksimenko A; Caron J; Mougin J; Desmaële D; Couvreur P
Int J Pharm; 2015 Mar; 482(1-2):38-46. PubMed ID: 25448549
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
[TBL] [Abstract][Full Text] [Related]
20. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]